Clinical Trials Browser

AZD 6244 × Dermatologic × Clear all

NCT01364051 2026-04-13

Cediranib Maleate and Selumetinib Sulfate in Treating Patients With Solid Malignancies

Phase 1 Active not recruiting

Melanoma

NCT00600496 2025-11-13

A Phase I, Open-Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6244 (ARRY-142886)

Phase 1 Active not recruiting

BreastDermatologicGastrointestinalGenitourinaryThoracic

Breast Neoplasms, Colonic Neoplasms, Kidney Neoplasms, Lung Neoplasms, Melanoma, Neoplasms

NCT01256359 2024-08-15

DOC-MEK

Phase 2 Completed

83 enrolled 60 charts

Melanoma

NCT02768766 2023-08-31

Intermittent Selumetinib for Uveal Melanoma

Phase 1 Completed

Uveal Melanoma, Melanoma

NCT02586987 2019-11-18

A Study to Assess the Safety, Tolerability and Anti-tumour Activity of Ascending Doses of Selumetinib in Combination With MEDI4736 and Selumetinib in Combination With MEDI4736 and Tremelimumab in Patients With Advanced Solid Tumours

Phase 1 Completed

BreastDermatologicGastrointestinalThoracic

Biliary Tract Neoplasms, Breast Neoplasms, Lung Neoplasms, Melanoma, Colorectal Neoplasms, Disease Progression

NCT01143402 2017-07-26

Temozolomide or Selumetinib in Treating Patients With Metastatic Melanoma of the Eye

Phase 2 Completed

120 enrolled 8 charts

Uveal Melanoma

NCT01974752 2017-01-05

SUMIT

Phase 3 Completed

152 enrolled 14 charts

Uveal Melanoma, Neoplasm Metastasis

NCT00936221 2016-03-14

Comparison of AZD6244 in Combination With Dacarbazine Versus (vs) Dacarbazine Alone in BRAF Mutation Positive Melanoma Patients

Phase 2 Completed

385 enrolled 11 charts

Melanoma

NCT00866177 2015-08-11

MEK Inhibitor AZD6244 in Treating Patients With Stage III or Stage IV Melanoma

Phase 2 Completed

167 enrolled 6 charts

Melanoma

NCT00338130 2014-08-13

Randomised Study to Compare the Efficacy of AZD6244 vs TMZ

Phase 2 Completed

Melanoma

NCT00710515 2014-08-13

Study to Assess the Effect of Dosing AZD6244 HydSulfate in the Presence and Absence of Food in Patients With Advanced Solid Malignancies

Phase 1 Completed

Melanoma

NCT01519427 2014-06-18

Selumetinib and Akt Inhibitor MK2206 in Treating Patients With Stage III or Stage IV Melanoma Who Failed Prior Therapy With Vemurafenib or Dabrafenib

Phase 2 Terminated

2 enrolled 9 charts

Melanoma

NCT01166126 2014-05-15

Temsirolimus/AZD 6244 for Treatment-naive With BRAF Mutant Unresectable Stage IV

Phase 2 Terminated

4 enrolled 7 charts

Melanoma